Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:IMR) ) is now available.
Imricor reported a strong start to 2026, entering the year with key U.S. FDA clearances for its NorthStar navigation system and Vision-MR diagnostic catheter, while also filing for 510(k) clearance of its Advantage-MR System. The company expanded its clinical trial footprint by adding major centers in the U.S. and Europe to its VISABL-AFL and VISABL-VT studies and moved to extend NorthStar’s use into paediatric settings, positioning itself for broader commercial adoption in the world’s largest electrophysiology market.
Commercially, Imricor is seeing growing inbound interest in NorthStar, with multiple customer quotes issued and initial U.S. sales expected in the second quarter, supported by a one-off investment in 40 RF-5000 generators as it shifts this equipment to in-house production. Quarterly operating cash outflows rose to US$7.8 million, including these investments and regulatory-related costs, but management expects outflows to moderate toward about US$6 million in the next quarter, with a cash and short-term investment balance of US$32.9 million at 31 March 2026 providing runway for its accelerating regulatory, clinical and commercial strategy.
The most recent analyst rating on (AU:IMR) stock is a Buy with a A$2.71 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.
More about Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
Imricor Medical Systems, Inc. is a medical technology company focused on real-time MRI-guided interventional electrophysiology procedures, developing systems and catheters for cardiac ablation in the electrophysiology market. The company targets U.S. and international hospitals, including children’s hospitals, aiming to reduce radiation exposure and establish MRI-guided interventions as a new standard of care.
Average Trading Volume: 350,253
Technical Sentiment Signal: Buy
Current Market Cap: A$645.1M
For detailed information about IMR stock, go to TipRanks’ Stock Analysis page.